Mark D Peterson1,2, Neil Kamdar2,3, Edward A Hurvitz1. 1. Department of Physical Medicine and Rehabilitation, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA. 2. Institute for Healthcare Policy and Innovation, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA. 3. Department of Obstetrics and Gynecology, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.
Abstract
AIM: To examine the longitudinal trends of cardiometabolic diseases in a large sample of adults with cerebral palsy (CP). METHOD: The Optum Clinformatics Data Mart is a de-identified nationwide claims database of beneficiaries from a single private payer. Beneficiaries were included if they had an International Classification of Diseases, Ninth Revision, Clinical Modification code for a diagnosis of CP. Adults with at least 3 years of continuous enrollment on a single plan between 2002 and 2009 were included in the final analyses (n=2659). We examined the longitudinal trends of incident diabetes mellitus, hypercholesterolemia, hypertension, cardiac dysrhythmias, and atherosclerosis, stratified by age categories: 18 to 39 years, 40 to 59 years, and 60 years and over. Kaplan-Meier product-limit survival curves were compared across age categories for each of the cardiometabolic outcomes, and a Cox proportional hazards regression was run to determine adjusted hazard ratios. RESULTS: The cumulative incidence of each of the cardiometabolic diseases ranged from 6.0% for atherosclerosis to 34.4% for hypercholesterolemia at 3 years and over. Risk-adjusted Cox proportional hazard models revealed that age was a robust predictor of survival for each outcome, with higher hazard ratio ranges in middle age (hazard ratio 1.41-2.72) and older adults (hazard ratio 2.20-5.93) compared with young adults. INTERPRETATION: Adults with CP have high rates of cardiometabolic diseases; and disease-free survival shortens significantly with higher ages. WHAT THIS PAPER ADDS: Adults with cerebral palsy have high rates of cardiometabolic diseases. Disease-free survival of all cardiometabolic diseases shortens significantly with higher ages. The highest rates were for hypercholesterolemia and hypertension.
AIM: To examine the longitudinal trends of cardiometabolic diseases in a large sample of adults with cerebral palsy (CP). METHOD: The Optum Clinformatics Data Mart is a de-identified nationwide claims database of beneficiaries from a single private payer. Beneficiaries were included if they had an International Classification of Diseases, Ninth Revision, Clinical Modification code for a diagnosis of CP. Adults with at least 3 years of continuous enrollment on a single plan between 2002 and 2009 were included in the final analyses (n=2659). We examined the longitudinal trends of incident diabetes mellitus, hypercholesterolemia, hypertension, cardiac dysrhythmias, and atherosclerosis, stratified by age categories: 18 to 39 years, 40 to 59 years, and 60 years and over. Kaplan-Meier product-limit survival curves were compared across age categories for each of the cardiometabolic outcomes, and a Cox proportional hazards regression was run to determine adjusted hazard ratios. RESULTS: The cumulative incidence of each of the cardiometabolic diseases ranged from 6.0% for atherosclerosis to 34.4% for hypercholesterolemia at 3 years and over. Risk-adjusted Cox proportional hazard models revealed that age was a robust predictor of survival for each outcome, with higher hazard ratio ranges in middle age (hazard ratio 1.41-2.72) and older adults (hazard ratio 2.20-5.93) compared with young adults. INTERPRETATION: Adults with CP have high rates of cardiometabolic diseases; and disease-free survival shortens significantly with higher ages. WHAT THIS PAPER ADDS: Adults with cerebral palsy have high rates of cardiometabolic diseases. Disease-free survival of all cardiometabolic diseases shortens significantly with higher ages. The highest rates were for hypercholesterolemia and hypertension.
Authors: Tudor Borza; Bruce L Jacobs; Jeffrey S Montgomery; Alon Z Weizer; Todd M Morgan; Khaled S Hafez; Cheryl T Lee; Benjamin Y Li; Hye Sung Min; Chang He; Scott M Gilbert; Jonathan E Helm; Mariel S Lavieri; Brent K Hollenbeck; Ted A Skolarus Journal: Urology Date: 2017-03-04 Impact factor: 2.649
Authors: Mark A Espeland; Eileen M Crimmins; Brandon R Grossardt; Jill P Crandall; Jonathan A L Gelfond; Tamara B Harris; Stephen B Kritchevsky; JoAnn E Manson; Jennifer G Robinson; Walter A Rocca; Marinella Temprosa; Fridtjof Thomas; Robert Wallace; Nir Barzilai Journal: J Gerontol A Biol Sci Med Sci Date: 2017-03-01 Impact factor: 6.053
Authors: Daniel G Whitney; Harshvardhan Singh; Freeman Miller; Mary F Barbe; Jill M Slade; Ryan T Pohlig; Christopher M Modlesky Journal: Bone Date: 2016-10-11 Impact factor: 4.398
Authors: Mark D Peterson; Peng Zhang; Heidi J Haapala; Stewart C Wang; Edward A Hurvitz Journal: Arch Phys Med Rehabil Date: 2015-07-02 Impact factor: 3.966
Authors: Matthew J Maenner; Stephen J Blumberg; Michael D Kogan; Deborah Christensen; Marshalyn Yeargin-Allsopp; Laura A Schieve Journal: Ann Epidemiol Date: 2016-01-12 Impact factor: 3.797
Authors: Daniel G Whitney; Edward A Hurvitz; Jennifer M Ryan; Maureen J Devlin; Michelle S Caird; Zachary P French; Elie C Ellenberg; Mark D Peterson Journal: Clin Epidemiol Date: 2018-05-01 Impact factor: 4.790
Authors: Daniel G Whitney; Sarah Bell; Daniel Whibley; Wilma M A Van der Slot; Edward A Hurvitz; Heidi J Haapala; Mark D Peterson; Seth A Warschausky Journal: Dev Med Child Neurol Date: 2020-05-10 Impact factor: 5.449
Authors: Ted Kheng Siang Ng; Patricia C Heyn; Alex Tagawa; Christina Coughlan; James J Carollo Journal: Front Neurol Date: 2022-06-27 Impact factor: 4.086
Authors: Daniel G Whitney; Seth A Warschausky; Daniel Whibley; Anna Kratz; Susan L Murphy; Edward A Hurvitz; Mark D Peterson Journal: Neurol Clin Pract Date: 2020-06